Results 81 to 90 of about 40,312 (250)

The effectiveness, safety and cost-effectiveness of cytisine versus varenicline for smoking cessation in an Australian population: a study protocol for a randomized controlled non-inferiority trial [PDF]

open access: yes, 2019
Smoking cessation medications are effective but often underutilised because of costs and side effects. Cytisine is a plant-based smoking cessation medication with over 50 years of use in Central and Eastern Europe.
Boland, Veronica C.   +19 more
core   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus   +5 more
wiley   +1 more source

A gender‐based secondary analysis of the ADAPT‐2 combination naltrexone and bupropion treatment for methamphetamine use disorder trial [PDF]

open access: green, 2023
Ximena A. Levander   +6 more
openalex   +1 more source

Cost-effectiveness analysis of pharmaceutical treatment options in the first-line management of major depressive disorder in Belgium [PDF]

open access: yes, 2014
The objective of this study was to assess the cost effectiveness of commonly used antidepressants as first-line treatment of major depressive disorder (MDD) in Belgium.
Annemans, Lieven   +5 more
core   +2 more sources

The real‐world relationship between naltrexone/bupropion treatment and weight loss in Canada: A retrospective chart review

open access: yesClinical Obesity, Volume 15, Issue 2, April 2025.
Summary This study examined the change in weight at 6 months of naltrexone/bupropion (NB), a combination pharmacological therapy for weight management, in real‐world practice in Canada. The study was conducted through an observational, retrospective, single‐arm chart review of adult patients who attended the Wharton Medical Clinic in Ontario, Canada ...
Sean Wharton   +4 more
wiley   +1 more source

GLP‐1 receptor agonists for treating obesity without diabetes: A systematic review and meta‐analysis of economic evaluations

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aim To pool the incremental net benefits (INBs) of using glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) for treating obesity without diabetes. Materials and Methods PubMed, Embase, EconLit, CEA Registry, ProQuest Dissertation and Theses Global were searched from inception to April 2024.
Teerapon Dhippayom   +7 more
wiley   +1 more source

Gender-related issues in the pharmacology of new anti-obesity drugs [PDF]

open access: yes, 2019
Four new medicines-liraglutide, lorcaserin, bupropion/naltrexone, and phentermine/topiramate-have been recently added to the pharmacological arsenal for obesity treatment and could represent important tools to manage this epidemic disease.
Barrea, Luigi   +6 more
core   +1 more source

Food and the brain: Neural and endocrine control of feeding, metabolism, and reproduction

open access: yesJournal of Neuroendocrinology, EarlyView.
Abstract Feeding and reproductive function are regulated by intricate systems that monitor food availability and energy stores, and on the basis of energy status, promote or put a brake on reproduction. This is particularly evident in the systems that regulate feeding and reproductive state in female mammals.
Naira da Silva Mansano   +2 more
wiley   +1 more source

Changing behaviour [PDF]

open access: yes, 2006
Individual change in behaviour has the potential to decrease the burden of chronic disease due to smoking, diet and low physical activity. Smoking quit rates can be increased by simple advice from a physician or trained counsellor, overall and in ...
Hillsdon, Melvyn   +2 more
core   +1 more source

Narcolepsy and rapid eye movement sleep

open access: yesJournal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Since the first description of narcolepsy at the end of the 19th Century, great progress has been made. The disease is nowadays distinguished as narcolepsy type 1 and type 2. In the 1960s, the discovery of rapid eye movement sleep at sleep onset led to improved understanding of core sleep‐related disease symptoms of the disease (excessive ...
Francesco Biscarini   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy